Cost-effectiveness analysis of tissue plasminogen activator in acute ischemic stroke in Iran.

CONCLUSIONS: The balance of hospitalization and rehabilitation costs and QALYs support the conclusion that treatment with intravenous tPA in the 4.5 hour time window is cost-effective from the perspectives of third party payer and inclusion of tPA in the insurance benefit package is reasonable. PMID: 29105528 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research